Objective: To estimate the risk of transient ischemic attack (TIA), stroke, and myocardial infarction in periods covering 4 weeks before to 52 weeks after herpes zoster (HZ) diagnosis in US adults. Patients and Methods: This retrospective study (GSK study identifier: HO-15-15771) with matched cohorts used the Truven Health MarketScan Commercial and Medicare claims data set linked with obesity and smoking status information. Patients 18 years and older at the date of HZ diagnosis and 1-year pre-and post-HZ diagnosis continuous insurance enrollment (from January 1, 2007, through December 31, 2014) were propensity score matched to controls in terms of demographic characteristics, risk factors for vascular events, other comorbid disorders, general health, obesity, and smoking status. A post hoc sensitivity analysis was performed not matching for obesity and smoking status information. Adjusted incidence rate ratios (IRRs) were estimated using multivariate Poisson models during an aggregate period (1-month before and after the index date). Results: A total of 23,339 patients with HZ were matched to 46,378 controls (mean age, 56 years; 45,173 [65%] women). During the aggregate period, patients with HZ were statistically significantly more likely to suffer a TIA: IRRs for all patients and patients aged 18 to 49 years were 1.56 (95% confidence interval [CI], 1.13-2.15) and 5.12 (95% CI, 1.37-19.10), respectively (P<.05); the respective IRRs for stroke were 1.40 (95% CI, 0.93-2.11) and 8.12 (95% CI, 0.93-71.27). In the sensitivity analysis, IRRs for TIA and stroke were statistically significantly increased regardless of age. Conclusion: Herpes zoster was associated with an increased risk of composite events, TIA, and stroke in adults in the period around diagnosis. More research on the HZ and vascular risk association is needed. 
H erpes zoster (HZ) is a painful localized vesicular rash with pustules and crusted vesicles usually localized to a single dermatome. 1, 2 When latent varicella zoster virus reactivates, presumably because of waning cell-mediated immunity, 3 the virus travels along the axons to the skin and causes HZ. 1 The reactivated virus may travel centrally, causing arterial inflammation and morphological changes that may result in ischemia and aneurysm. [4] [5] [6] Herpes zostereassociated vasculopathy may be cranial or extracranial and may result in transient ischemic attack (TIA) and stroke. 5 Over the past few years, an association between HZ and an increased risk of stroke, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] TIA, 7, 9, 16, 20 myocardial infarction (MI), 7, 11, 16 and acute coronary syndrome 21 has been supported by several studies [7] [8] [9] [10] [11] [17] [18] [19] [20] [21] and meta-analyses, [12] [13] [14] [15] [16] 22 most of which were conducted outside the United States. In the United States, data are limited to only 3 studies that reported an increased likelihood of MI 10 and stroke 11, 17 after HZ. Given that HZ affects up to 1 million people a year in the United States 23 and the incidence of HZ in the United States has been gradually increasing over time in adults older than 65 years, 24, 25 there is a need for large, rigorously conducted US studies exploring the HZ and vascular risk association.
We therefore aimed to estimate the risk of TIA, stroke, and MI after the first HZ diagnosis compared with a matched cohort of patients without HZ by using a large national insurance claims database. The risk was evaluated in periods covering 4 weeks before to 52 weeks after HZ diagnosis in adults.
PATIENTS AND METHODS

Study Design and Data Sources
This longitudinal retrospective cohort study (GSK study identifier: HO-15-15771) used 2007 to 2014 data from the Truven Health MarketScan Commercial and Medicare Supplemental databases linked to a primary care electronic medical record (EMR) database (EMR-claims linked database); the EMR database was used to obtain additional variables such as patients' height, weight, and smoking status. Adult patients with a first HZ diagnosis were matched for age, sex, body mass index (BMI, calculated as the weight in kilograms divided by the height in meters squared), smoking status, insurance plan type, and clinical characteristics (see below) to patients with no HZ diagnosis (controls) by using propensity score analysis. The incidence rates of vascular events in the HZ cohort and matched controls were compared. A post hoc sensitivity analysis not using data from the EMR database was performed to provide larger sample sizes, because neither smoking nor BMI was significant adjusting factors in the primary analysis (.22<P<.77). All database records were de-identified, fully adherent to US patient confidentiality requirements, and exempt from institutional review board approval.
Study Timelines, Data Collection, and Follow-up Periods The study period was from January 1, 2007, through December 31, 2014 . The date of the first HZ diagnosis was the index date. A minimum of 1 year of continuous enrollment before the index date was used as the baseline period. Therefore, the earliest index date in this study was January 1, 2008.
Outcome assessment was performed for the following periods: 4 weeks up to the index date (prodromal period); 4 weeks before to 4 weeks after the index date (aggregate period); the periods of weeks 1 to 4, weeks 5 to 12, weeks 13 to 26, weeks 27 to 52 after the index date; and the entire follow-up period from 4 week before to 1 year after the index date (but not later than December 31, 2014).
Participants
Eligibility Criteria. Eligible patients (1) had a first HZ diagnosis claim (referred to as diagnosis hereafter) with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis code (053.xx) made on or after January 1, 2008, and before June 30, 2014; (2) were 18 years and older at the index date; and (3) had continuous enrollment in the claims database for 12 months or more before the index date, and up to 1 year after. Patients were excluded from analyses if they were found to have (1) had an HZ diagnosis during the baseline period; (2) had an index diagnosis for postherpetic neuralgia (ICD-9-CM diagnosis code 053.12 or 053.13, indicating continued care for a previous episode of HZ); (3) had received HZ vaccine at any time; (4) had a diagnosis of TIA, stroke, or MI during the baseline period excluding the prodromal period; or (5) had no available smoking status or BMI data (not applied for the follow-up post hoc sensitivity analysis).
Matched Controls. The control group consisted of patients with no HZ diagnosis during the study period matched to patients with HZ using propensity scores: the list of patients without HZ during the study period was extracted from the database, and then the index dates of the eligible patients with HZ were randomly assigned to them; subsequently, they were screened according to the study eligibility criteria to create the final control group.
Matching
Primary Analysis. Propensity scores were estimated using a logistic regression model including covariates (see below). Once the propensity score had been estimated (Supplemental Methods, available online at http://www.mayoclinicproceedings.org), patients with HZ diagnosis were matched to patients with no HZ diagnosis in a 1:2 ratio wherever possible (if not possible, a 1:1 ratio was used) by using a radius matching technique without replacement and enforcing a caliper of 0.25 times the SD of the propensity score.
Post Hoc Sensitivity Analysis. The post hoc sensitivity analysis could not obtain a good propensity score match, which appeared to be driven by baseline health care expenditures, and thus a 1:1 direct matching was performed using the covariates listed below while excluding baseline health expenditures.
Covariates
Patient demographic and other characteristics were recorded to describe the sample and were made available for use in the multivariate models (see below). These included age (in years) at the index date, sex, geographic region based on the primary health plan subscriber's home address in the US Census Bureau geographic regions (Northeast, North Central, South, West, or unknown), total health care expenditures (health care utilization including all-cause costs) during the baseline period, insurance plan type (comprehensive, exclusive provider organization, health maintenance organization, point of service, preferred provider organization, point of service with capitation, consumer-driven health plan, or other).
Baseline comorbidities 26 and medications were recorded and included antiviral treatment of HZ and anticoagulants (Supplemental Tables 1, 2 , and 3, available online at http://www.mayoclinicproceedings. org). The Deyo-Charlson comorbidity index 27 was also included, a measure of comorbidity expressed as a numeric score based on the presence of selected diagnoses for various conditions, each with specific weightings ranging from 1 to 6 points (Supplemental Table 4 
Statistical Methods
Demographic and clinical variables were reported for all study participants, and bivariate comparisons were performed using appropriate statistical tests: chi-square tests for categorical variables and paired t tests or nonparametric 2-sample tests for continuous and numerical variables.
The unadjusted incidence rates of composite events, TIA, stroke, and MI were calculated during the prodromal and follow-up periods. The formula used to calculate incidence was as follows: event rate¼sum of events counts/sum of total person-time at risk. Person-time at risk included the time from the beginning of the prodromal period to the end of followup for each patient. The proportion of patients with an event and event counts were calculated. Bivariate comparisons between the HZ cohort and controls were performed. To determine the relative risk over time for patients with HZ compared with their matched controls, the assumption of proportional hazard was tested by plotting Kaplan-Meier survival curves.
The adjusted incidence rates were determined for composite events, TIA, and stroke by using a Poisson model, adjusting for covariates. Models for the post hoc sensitivity analysis did not include smoking status and BMI information. Incidence rates per 1000 person-years, incidence rate ratios (IRRs), and 95% CIs are given.
Bivariate and multivariate analyses were performed in the overall matched cohort, and the results were stratified by age (<50 and !50 years).
Statistical analyses were performed using SAS version 9.4 (SAS Institute).
RESULTS
Patients
Primary Analysis. A total of 1,366,743 adults had an HZ diagnosis during the study period, of whom 725,527 were enrolled according to the study eligibility criteria. Of those who met HZ eligibility criteria and also had EMR data on BMI and smoking, 23,418 patients remained eligible for the primary analysis. The propensity score match was excellent, with 23,339 patients with HZ (99.7%) matched in an approximately 1:2 ratio to 46,378 controls. A total of 23,039 of patients with HZ could be matched to 2 controls (Supplemental Table 5 , available online at http://www.mayoclinic proceedings.org). Covariate balance was greatly improved after the matching procedure, with no standardized differences above 10%.
Post Hoc Sensitivity Analysis. A total of 709,252 patients (97.8%) could be successfully matched to a control patient in a 1:1 ratio (Supplemental Table 6 , available online at http://www.mayoclinicproceedings.org).
Descriptive Data
Participants (patients with HZ and controls) in both analyses were mostly women and had a mean age somewhat higher than 50 years (Table 1) . Most were living in urban areas and were enrolled in commercial insurance schemes. Deyo-Charlson comorbidity index scores averaged below 1, with the most common comorbidities being diabetes and chronic pulmonary disease (Table 1) . Common noneDeyo-Charlson comorbidity index comorbidities included hypertension, hypercholesterolemia or hyperlipidemia, and coronary artery disease. A quarter of participants were of normal weight, and a similar percentage were previous smokers (Table 1) .
Bivariate ComparisonsdEvents, Incidence Rates, Unadjusted IRRs, and Kaplan-Meier Survival Curves Primary Analysis. The number of events and unadjusted incidence rates per 1000 person-years are summarized in Table 2 . Significant differences in incidence rates were observed (1) over the entire follow-up period for TIA and MI, (2) for the index date for composite events and TIA, (3) during weeks 5 to 12 and weeks 13 to 26 for MI only, and (4) over the aggregate period for the composite events and TIA. The incidence rates of MI were lower in patients with HZ than in controls, but the incidence rates of TIA were higher ( Table 2 ).
The unadjusted IRRs were similar. During the aggregate period and the entire follow-up period, patients with HZ were more likely to have TIA, and during the entire follow-up, they were less likely to have MI (Supplemental Table 7 , available online at http://www.mayoclinicproceedings. org).
The stratification by age yielded higher unadjusted incidence rates of composite events and TIA in patients with HZ aged 18 to 49 years over the aggregate period (Supplemental Table 8 , available online at http://www.mayoclinicproceedings.org).
Most events occurred on the index date, as shown in Kaplan-Meier survival curves in the Figure. Post Hoc Sensitivity Analysis. The post hoc sensitivity analysis yielded additional statistically significant differences in unadjusted incidence rates per 1000 person-years between patients with HZ and controls in comparison to the primary analysis (Table 3 ). The HZ cohort had higher TIA incidence rates at all time periods and higher composite events, stroke, and MI incidence rates from the index date up to week 4. The age-stratified results indicated additional statistically significant differences in unadjusted rates between patients with HZ and controls in comparison to the primary analysis (Supplemental Table 8 ). Among the 18-to 49-year age group, these additional statistically significant differences were observed for the higher incidence rates in patients with HZ for stroke during the aggregate period and for composite events, stroke, and TIA during the entire follow-up period. Among the 50-year and older age group, these involved all comparisons except MI during the aggregate period.
US ZOSTER VASCULAR EVENTS: RETROSPECTIVE ANALYSIS
Multivariate ModelsdAdjusted IRRs
Multivariate models were run for the aggregate period. Previous bivariate comparisons had shown that this was the period most likely to include a vascular event; MI events were not increased and therefore excluded from this analysis.
Primary Analysis. The adjusted IRRs for the aggregate period indicated that patients with HZ aged 18 to 49 years were statistically significantly more likely to suffer a TIA or composite events (Table 4) .
Post Hoc Sensitivity Analysis. Regardless of age, the likelihood of suffering a TIA, stroke, or composite events was statistically significantly higher in patients with HZ (Table 4) .
DISCUSSION
We conducted the largest US study using a national sample to investigate the association between the development of HZ and the occurrence of TIA, stroke, and MI in a population of adult patients with HZ compared with matched controls. Overall, we found statistically significantly increased risk of TIA and stroke in adult patients with HZ as compared with those without. However, consistency of the findings over time and age varied with respect to sampling of the population and when controlling for known cardiovascular risk factors. Incorporation of these new findings, considering available evidence, is important when making clinical recommendations in situations in which preventive measures are recommended (adults 50 years and older) 28 and highlights the need for additional research that can guide researchers and policymakers in additional evidence needed to address younger adults (18-49 years old). The Supplemental Figure ( available online at http://www.mayoclinicproceedings.org) summarizes the context, outcomes, and impact of this study for health care professionals.
Our study's rigorous matching of patients with HZ to controls by using 2 approaches across 2 sampling strategies is an important strength that adds to the existing literature. Only 1 previous study used a propensity scoreematching approach, 29 whereas our study incorporated both propensity score (resulting in significant patient attrition) and direct matching, without controlling for 2 known cardiovascular risks, BMI, and smoking. In doing so, this study also adds a unique perspective on potential etiologies of vascular end points as identified in risk factor measurement. If one believes that HZ represents a fundamentally different mechanism 5 for vascular disease based on a transient inflammatory process contrasted with more traditional risk factors associated with obesity or smoking, then the nuance of the results of this study potentially amplify the need for further research, especially in younger adults.
Our primary analysis results over the aggregate period revealed a 56% higher risk of suffering a TIA. Only one other study specifically assessed the association between TIA and HZ
7
; the other studies included TIA as part of a composite vascular event together with stroke. 9, 20 In their study with a median follow-up of 6.3 years, Breuer et al 7 reported a 15% increase in the risk of suffering a TIA in their population of 106,601 patients with HZ (adjusted hazard ratio, 1.15; 95% CI, 1.09-1.21). Our findings agree with these, also with regard to the increased risk reported in younger patients with HZ (adjusted hazard ratio in the HZ group aged 18-40 years, 2.42; 95% CI, 1.34-4.36).
Yawn et al 10 focused on patients with HZ older than 50 years; they matched patients with HZ to controls in terms of age and sex and controlled for confounders by using multivariate logistic regression, but did not include obesity or smoking status. The odds of suffering a stroke and MI were, respectively, 1.53 and 1.68 higher in the 3 months after HZ. This study design is closer to our sensitivity analysis, and findings are in good agreement. Similar to our primary analysis, Breuer et al 7 did not see statistically significant increases in stroke using Cox proportional hazards regression (hazard ratio, 1.02; 95% CI, 0.98-1.07) after adjustment for risk factors, including obesity and smoking status. Minassian et al 11 conducted a self-controlled case series study in US patients 65 years and older. In the first week and weeks 2 to 4 after HZ diagnosis, they reported a marked increase in the rate of stroke (2.37-and 1.55-fold, respectively) in comparison to their "unexposed" period, which started before HZ diagnosis (at the beginning of the study's observation period) up to the end of study follow-up (median, 5 years); the day of HZ diagnosis, 4 weeks before HZ diagnosis, and 52 weeks after HZ diagnosis were excluded from the unexposed period. Differences in the choice of controls, periods for between-group comparisons, and controlling for confounders greatly affect outcomes; thus, the results of these studies are barely comparable, as also indicated by the high I 2 heterogeneity index recorded in the meta-analyses of the association between HZ and stroke. [12] [13] [14] [15] Future Perspectives and Vaccination With an increasing HZ incidence 24, 25 in the United States, our findings and earlier studies indicate that HZ development is a short-term risk factor for vascular events in adults. The US Advisory Committee on Immunization Practices recently expanded its HZ vaccination recommendation 30 to include younger people (from !60 to !50 years of age). 28 It has also been suggested that all adults with established vascular risk factors should be vaccinated against HZ irrespective of age. 7 However, because only recently it has been advised to explore risk factors for vascular disease in women younger than 50 years and men younger than 40 years, questions remain at what level of increased risk or which population benefit most from earlier intervention. 31, 32 Despite recommendations, vaccination coverage was only 3% in Medicare beneficiaries between 2006 and 2011 11 and 30.6% in the overall US population 60 years and older. 33 Initiatives to increase awareness about HZ burden of disease and complications should be implemented, as findings suggest that awareness of complications through a personal experience (eg, spouse with HZ) significantly increases the vaccination rate. 34 Limitations Administrative claims data are subject to data coding limitations and data entry error; therefore, there is potential for misclassification of our study covariates or outcomes. Despite this, we anticipated that the extent of misclassifications of this type would be similar in both patients with HZ and matched controls. In addition, information on race and socioeconomic status were not available for analysis. This study is limited only to patients covered by commercial health insurance or supplemental insurance through Medicare, and its findings may not be representative of the entire US population.
CONCLUSION
Herpes zoster was associated with a statistically significant increase in the risk of composite events, TIA, and stroke in adults in the period around diagnosis. However, the rate of vascular complications associated with HZ appears transient in nature, diminishing in significance and returning in magnitude to that of the general ageadjusted population rates by 1 year after HZ. More research on the HZ and vascular risk association is needed to guide the development of interventions and policies enabling prevention for adults.
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